The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | EXPLORER: Avapritinib in systemic mastocytosis
Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, presents findings from a mutational analysis of the Phase 1 EXPLORER trial (NCT02561988), which assessed avapritinib in patients with advanced systemic mastocytosis (AdvSM) and an associated hematologic neoplasm (AHN), primarily driven by KIT D816V mutations. Treatment with avapritinib in patients reported superior survival outcomes and significantly reduced KIT D816V disease burden in the majority of patients. Re-emergence of the mutations was additionally rarely seen in the patient cohort. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
